Publicaciones en las que colabora con Enrique Raviña Rubira (8)

2017

  1. 3-Oxopyridazin-5-yl-Chalcone Hybrids: Potent Antiplatelet Agents That Prevent Glycoprotein IIb/IIIa Activation

    ChemistrySelect, Vol. 2, Núm. 17, pp. 4920-4933

2007

  1. Design, synthesis, and structure-activity relationships of a novel series of 5-alkylidenepyridazin-3(2H)-ones with a non-cAMP-based antiplatelet activity

    Journal of Medicinal Chemistry, Vol. 50, Núm. 26, pp. 6476-6484

2006

  1. Pyridazines part 41: Synthesis, antiplatelet activity and SAR of 2,4,6-substituted 5-(3-oxo-3-phenylprop-1-en-1-yl)- or 5-(3-phenylprop-2-enoyl) pyridazin-3(2H)-ones

    Bioorganic and Medicinal Chemistry Letters, Vol. 16, Núm. 4, pp. 1080-1083

2004

  1. Pyridazines. Part 36: Synthesis and antiplatelet activity of 5-substituted-6-phenyl-3(2H)-pyridazinones

    Bioorganic and Medicinal Chemistry Letters, Vol. 14, Núm. 2, pp. 321-324

2002

  1. Pyridazines. Part 31: Synthesis and antiplatelet activity of 4,5-disubstituted-6-phenyl-3(2H)-pyridazinones

    Chemical and Pharmaceutical Bulletin, Vol. 50, Núm. 12, pp. 1574-1577

1999

  1. Pyridazines XVIII. 6-Aryl-3(2H)-pyridazinones inhibit calcium influx in stimulated platelets

    Biological and Pharmaceutical Bulletin, Vol. 22, Núm. 12, pp. 1376-1379

1997

  1. Pyridazines. XIII. Synthesis of 6-aryl-5-oxygenated substituted-3(2H)- pyridazinones and evaluation as platelet aggregation inhibitors

    Chemical and Pharmaceutical Bulletin, Vol. 45, Núm. 7, pp. 1151-1155

1993

  1. Pyridazine derivatives. XI: Antihypertensive activity of 3‐hydrazinocycloheptyl[1,2‐c]pyridazine and its hydrazone derivatives

    Journal of Pharmaceutical Sciences, Vol. 82, Núm. 3, pp. 286-290